September 8, 2009 (FinancialWire) — Oxygen Biotherapeutics, Inc. (OTCBB: OXBO) (Current Market Cap: $129.22 Mil.) said it is asking shareholders to approve a one-for-15 reverse stock split at the company’s annual meeting on October 19.

The company is seeking a listing change on a major exchange, and said the reverse split would help it meet minimum share price requirements.

Durham, North Carolina-based Oxygen Biotherapeutics is focused on commercializing pharmaceuticals and medical devices in the field of oxygen therapeutics and defense medicine.

The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product and has out-licensed an implantable glucose sensor.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.